Jenny Richardson

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

DSK Hyp AG provides banking and financial services to corporate customers, institutions and private individuals. The bank operates through corporate and institutions division which comprises of merchant banking and securities. The company is headquartered in Frankfurt am Main, Germany.

GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada.

Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London.

The Law Society of Upper Canada engages in the provision of legal services. The company was founded in 1797 and is headquartered in Toronto, Canada.

EyeSense GmbH develops novel ophthalmic self-diagnostic systems for glucose monitoring of diabetes patients. It is developing two different diagnostic systems: An ophthalmic sensor which-once inserted on the eye-can be read out optically as frequently as wanted, without any pain and a continuous sensor, to be worn on the abdomen or upper arm. The firm with its innovative sensor technology able to offer two products that addresses different needs in blood glucose monitoring which are Continuous Glucose Sensor and Eye Sensor. The company was founded in 2006 and is headquartered in Großostheim, Germany.

STI Technologies Ltd. provides marketing solutions to the health care industry. The firm's SmartTechnology platform allows stakeholders-manufacturers, pharmacies, prescribers, and payers to optimize their patient relationships. It offers solutions for pre-launch planning, brand adoption, market uptake, revenue optimization, retention and adherence, and loss of exclusivity. The company was founded by William B. Adams and Gregory Patey in 2001 and is headquartered in Halifax, Canada.

Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway.

Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.

Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.

Part of GSK Plc, GlaxoSmithKline AB is a Swedish pharmaceutical company that manufactures pharmaceutical products.

Pergamum AB develops, registers, markets, and trades pharmaceutical products based on therapeutic peptides. The company was founded on June 18, 2008 and is headquartered in Solna, Sweden.

Part of Roche Holding AG, Roche AB is a biotechnology company founded in 1896. The company is based in Solna, Sweden and creates innovative treatments to help millions of patients worldwide. Roche actively seeks partnerships with healthcare providers, academia, patient associations, organizations, external companies, and startups to identify needs that form the basis for collaborations. Roche is one of the world's largest research-based biotechnology companies, focusing on advancing science to improve people's lives. The Swedish company develops both drugs and diagnostics and has great respect for the multiple perspectives required to create tomorrow's healthcare.

Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland.

Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden.

Badertscher Rechtsanwälte AG is a national and internationally recognized law firm specializing in business, tax, and notary law, with offices in Zurich and Zug, Switzerland. The firm provides legal services to Swiss and foreign companies, public institutions, and individuals. The team of two dozen lawyers offers comprehensive legal advice in private and public law. The firm's approach is holistic, efficient, and solution-oriented, with a focus on tailored solutions that meet clients' needs. The firm's areas of expertise include insurance and liability law, corporate law, and public law. The firm also offers career opportunities for lawyers interested in joining their team.

Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.

KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden.

M Von Euler Consulting AB operates as a scientific and technical research & development organization. M Von Euler Consulting AB is based in Stockholm, Sweden. Curt Mikael von Euler-Chelpin has been the CEO of the Swedish company since 2014.

Bostadsrättsföreningen Mälarvik operates as a housing association.

Goesch Pharma Pte Ltd. is a Singaporean company that wholesales pharmaceutical products. The private company is based in Singapore, Singapore.

Founded in 2018, GH Research Ireland Ltd. is an Irish clinical-stage biopharmaceutical company that develops innovative therapies for the treatment of mental illnesses. The company is based in Dublin, Ireland and is a subsidiary of GH Research Plc.

AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021.